Skip to main content
Clinical Trials/NCT04389099
NCT04389099
Completed
Not Applicable

MRI Angiography of Physiological and Pathological Pregnancy Placentas Ex-vivo

Central Hospital, Nancy, France1 site in 1 country84 target enrollmentNovember 18, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Pre-Eclampsia
Sponsor
Central Hospital, Nancy, France
Enrollment
84
Locations
1
Primary Endpoint
Placental vasculature architecture indice: placental artery density (cm3)
Status
Completed
Last Updated
last year

Overview

Brief Summary

Introduction:

The placenta is the organ that permits the maternal-fetal exchange of the oxygen and nutrients. The development of its vascular network occurs in the first trimester. Any deficit during this important angiogenesis procedure can lead to the dysfunction of the placental vasculature, which can potentially cause pathologies including preeclampsia (PE) and intrauterine growth restriction (IUGR). PE concerns 3% of the pregnancy in France. It can occur at any gestational age and leads to serious complications such as eclampsia, the HELLP syndrome or the retro-placental hematoma. IUGR does not only lead to the morbidity and fetal and neonatal mortality, but also has a predisposition for certain pathologies in the adulthood.

Many groups have studied the placenta vasculature at the microscopic (histological) scale. However, recent studies show that in addition to the damage at the microvasculature level, the macroscopic placental vessel architecture is also altered. Nonetheless, the origin and the etiology of this phenomenon remains unknown.

Since it is difficult to apply in-vivo imaging techniques on pregnant women due to the restriction of usage of contrast agent. Alternatively, ex-vivo MR angiography (MRA) techniques have been developed by our team and others to visualize the entire placental vasculature in a faster way (as compared to corrosion casting). Up to now, only the study of the healthy placenta is done and published. The analysis of the pathological placental vasculature (i.e. PE and IUGR cases) at different gestational age and its comparison to the physiological ones have not been conducted, which will potentially enable a better understanding of the placental vasculature pathology.

Objectives: the main objective of this study is to compare the vasculature architecture of the normal and pathological placentas (with possible alteration in the placental vasculature).

Methods and analysis: This is a monocentric, prospective, controlled but not randomized study. The investigators expect to include 110 women in Nancy. The pregnant women will be recruited when they arrived at the maternity hospital for delivery, for both the physiological and potential pathological cases. The notice of this study will be given. If no opposition is given by the subject, the placenta may be collected. This study will not collect the patient consent but only the opposition declaration will be collected.

Registry
clinicaltrials.gov
Start Date
November 18, 2019
End Date
November 17, 2024
Last Updated
last year
Study Type
Observational
Sex
Female

Investigators

Sponsor
Central Hospital, Nancy, France
Responsible Party
Principal Investigator
Principal Investigator

BERTHOLDT Charline

Principal Investigator (gynecologist-obstetrician)

Central Hospital, Nancy, France

Eligibility Criteria

Inclusion Criteria

  • already received the complete information about the study and do not express any opposition to the utilisation of their data
  • mandatory enrolment in a social security plan
  • gestational age more than 30 weeks (and until at term)
  • patient with either natural delivery or with cesarean section and whose placenta is naturally completely separated (directed delivery only)

Exclusion Criteria

  • younger than 18 years old
  • new borns with congenital disease (either suspected at birth or already diagnosed)
  • presence of only one umbilical artery
  • presence of a maternal pathology: gestational or pre-existing diabetes, autoimmune diseases that may have an impact on placental vascularization (Antiphospholipid Antibody Syndrome, Immune Thrombocytopenia, Myasthenia, Systemic Lupus Erythematosus), cancer,
  • do not speak the French language, or inability to understand the given information of the study
  • manual delivery
  • incomplete placenta
  • placenta with true marginal insertions (cord insertion within 1 cm of the placental margin) and/or velaments of the cord
  • Person referred to Articles L.1121-6 and L-1121-8 of the Public Health Code

Outcomes

Primary Outcomes

Placental vasculature architecture indice: placental artery density (cm3)

Time Frame: through study completion, on average of 24 months

Placental vasculature architecture indice: placental vessel tortuosity

Time Frame: through study completion, on average of 24 months

Placental vasculature architecture indice: placental vessel tree branching

Time Frame: through study completion, on average of 24 months

Placental vasculature architecture indice: placental vien density (cm3)

Time Frame: through study completion, on average of 24 months

Placental vasculature architecture indice: total vascular density

Time Frame: through study completion, on average of 24 months

Study Sites (1)

Loading locations...

Similar Trials

Completed
Not Applicable
Placenta Imaging ProjectHigh Risk Pregnancy
NCT02749851Oregon Health and Science University379
Completed
Not Applicable
Advanced MRI for Uteroplacental Flow, Perfusion, Oxygenation & InflammationPregnancyObesityPreeclampsia
NCT02791568University of Wisconsin, Madison121
Completed
Not Applicable
MARS: Magnetic Resonance Study: A Novel Assessment of Placental FunctionPlacenta Diseases
NCT03764878NorthShore University HealthSystem15
Not yet recruiting
Not Applicable
A Novel Approach Integrating Magnetic Resonance Imaging (MRI) Data and Artificial Intelligence for Predicting the Success Rate of Vaginal Delivery in Pregnant WomenVaginal Delivery
NCT06044129Second Affiliated Hospital of Wenzhou Medical University200
Active, not recruiting
Not Applicable
Maternal, uteroplacental and fetal haemodynamic effect of Nicardipine in severe pre-eclampsia. - CORCA IIHypertensive crisis in patients with severe pre-eclampsia needs to be treated to prevent maternal and fetal complications. The maternal, uteroplacental and fetal haemodynamic respose to antihypertensive treatment with Nicardipinehydrochloride will be evaluated in detail by materal echocardiography and fetal doppler ultrasound as well as by the effect on plasma Brain Natriuretic Peptide concentration (BNP) and parameters of the Renin- Angiotensin- Aldosterone system (RAAS).MedDRA version: 9.1Level: LLTClassification code 10040445Term: Severe pre-eclampsia, antepartumMedDRA version: 9.1Level: LLTClassification code 10053094Term: Doppler echocardiographyMedDRA version: 9.1Level: LLTClassification code 10045412Term: Ultrasound DopplerMedDRA version: 9.1Level: LLTClassification code 10058179Term: Hypertensive emergencyMedDRA version: 9.1Level: LLTClassification code 10038555Term: ReninMedDRA version: 9.1Level: LLTClassification code 10002491Term: Angiotensin IIMedDRA version: 9.1Level: LLTClassification code 10053406Term: Brain natriuretic peptideMedDRA version: 9.1Level: LLTClassification code 10001644Term: Aldosterone
EUCTR2007-000727-17-NLErasmus MC10